* Cel-Sci Corp., of Alexandria, Va., completed a $1.15 million privatefinancing in which 575,000 units _ consisting of one share and onewarrant _ were sold.

* Cyanotech Corp., of Kailua-Kona, Hawaii, licensed rights from theUniversity of Memphis to manufacture and sell a genetically alteredmicroalgae that is toxic to mosquito larvae. The modified algae containa toxin gene from bacteria called bacillus thuringiensis israelensis andare designed to control mosquito-infested water.

* Duke University Medical Center, of Durham, N.C., and ExVivoTherapies _ a joint venture between Applied Immune Sciences Inc.and Rhone-Poulenc Rorer Inc. _ are collaborating to construct andoperate a cell-processing center for growing and enhancing thetherapeutic effects of human cells. It is the first such collaborationbetween an academic center and industry, the companies said.

* Genetic Therapy Inc., of Gaithersburg, Md., initiated a Phase I/II trialof its Hs-tk gene therapy product to treat malignant brain tumors inchildren.

* Gensia Inc., of San Diego, received approval in Denmark to marketits GenESA system.

* Switzerland-based Ciba-Geigy Ltd. made a $3 million equityinvestment in Isis Pharmaceuticals Inc., of Carlsbad, Calif., bypurchasing 200,000 Isis shares for $15 per share. Ciba paid a premiumof $4 per share to Isis' closing stock price June 28 of $11 per share.

* Xoma Corp., of Berkeley, Calif., started a Phase II trial in theNetherlands of Neuprex for complications, such as infections, resultingfrom surgical removal of a portion of the liver. Neuprex is designed asa bactericidal and endotoxin neutralizing agent.

* Genzyme Tissue Repair, of Cambridge, Mass., said the FDA doesnot intend to regulate the Carticel cartilage cell service at this time,resulting in resumption of the service.

* T Cell Sciences Inc., of Needham, Mass., completed patient accrualin its Phase I trial of TP10 (soluble complement receptor 1) in adultrespiratory distress system.

* Immunomedics Corp., of Morris Plains, N.J., said the OppositionDivision of the European Patent office decided to maintain thecompany's patent for specific antibodies for carcinoembryonic antigen.The opposer, Behringwerke AG, of Germany, did not appeal.

* GeneMedicine Inc., of The Woodlands, Texas, extended CorangeInternational's exclusive option for an alliance, until July 17, todevelop certain gene medicines for cancer.

* The Liposome Co., of Princeton, N.J., said its new drug applicationfor ABLC, submitted in May, was accepted by the FDA.

* Agouron Pharmaceuticals Inc., of La Jolla, Calif., was cleared by theFDA to extend Phase II trials of the anti-HIV drug AG1343 into theU.S.

* University of Pittsburgh scientists received a $2.5 million grant fromthe National Cancer Institute to develop cancer drugs based onselective inhibition of the ras gene.

* Genta Inc., of San Diego, further restructured to save money. Themove eliminated certain officer positions, including that of formerpresident William Bliss.

* U.S. Bioscience Inc., of West Conshohocken, Pa., signed anexclusive marketing and distribution agreement for Hexalen andNeuTrexin in Europe with Beaufour Ipsen, a privately held Frenchpharmaceutical company.

* Corvas International Inc., of San Diego, said data reported at asymposium in Germany showed its neutrophil inhibitory factor reducedbrain injury in an animal model of stroke.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., submitted amarketing authorization application in Europe for use of Rilutek totreat amyotrophic later sclerosis.

* Neurogen Corp., of Branford, Conn., said Schering-Plough Corp.directors approved an agreement to enter a strategic alliance related toschizophrenia and other disorders. Neurogen received $17 million asan initial payment (See BioWorld Today, June 16, 1995, p.1).

(c) 1997 American Health Consultants. All rights reserved.

No Comments